Clinical experience with insulin detemir in patients with type 2 diabetes from the near East Countries

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 399-408

  Echtay, Akram ^a   Tsur, Anat ^b   Hasan, Mohammad I ^c   Abu Hijleh, M Omar ^d   Khatib, Nidal Al ^e   Andari, Emile ^f   Atallah, Paola ^g   Qureshi, Saleem ^h   Zafar, Jamal ⁱ   Sandalci, Levent ^j   Ademogullari, Asude ^j   Haddad, Jihad ^k   Dagan, Bracha ^b  

^a RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^b CLALIT HEALTH SERVICES   (Israel)

^c Diabetic Institute of Pakistan   (Pakistan)

^d JORDAN HOSPITAL   (Jordan)

^e Islamic Hospital   (Jordan)

^f Notre Dame des Secours University Hospital Center   (Lebanon)

^g Saint Georges University Medical Hospital   (Lebanon)

^h KRL Hospital   (Pakistan)

ⁱ PAKISTAN INSTITUTE OF MEDICAL SCIENCES   (Pakistan)

^j NOVO NORDISK A S   (Denmark)

^k Division of Endocrinology   (Jordan)

more..

Author keywords

Insulin detemir; Near East; Observational study; Type 2 diabetes

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; METFORMIN; REPAGLINIDE; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BONE PAIN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84899854535     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0041-z     Document Type: Article

References (28)

1. Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? Clin Diabetes. 2009;27:60-8.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
3. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(Suppl. 1):S11-61.
4. Davis S, Alonso MD. Hypoglycemia as a barrier to glycaemic control. J Diabetes Complicat. 2004;18:60-8.
5. Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int. 2003;20:63-71.
6. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48:1988-95.
7. Keating GM. Insulin detemir: a review of its use in the management of diabetes mellitus. Drugs. 2012;72:2255-87.
8. Ferriss JB, Webb D, Chaturvedi N, Fuller JH, Idzior-Walus B, EURODIAB Prospective Complications Group. Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure in type 1 diabetes. Diabet Med. 2006;23:557-64.
9. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-12.
10. Mathieu C. Engineering basal insulin-clinical evidence translating to clinical experience. JAPI. 2009;57:16-21.
11. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201.
12. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
13. Khunti K, Caputo S, Damci T, et al; On behalf of the SOLVE Study Group. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab. 2012;14:1129-36.
14. Dornhorst A, Luddeke HJ, Sreenan S, et al; PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008;62:659-65.
15. Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium; 2011, updated 14 November 2012. http://www.idf.org/diabetesatlas/5e. Accessed 23 September 2013.
16. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21.
17. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
18. Breum L, Almdal T, Eiken P, Lund P, Christiansen E, Danish BIAsp Study Group. Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study. Rev Diabet Stud. 2008;5(3):154-62.
19. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes. Diabetologia. 2008;51(3):408-16.
20. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucoselowering drugs. Diabetes Care. 2010;33(6):1176-8.
21. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999;42:406-12.
22. Raslová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27:279-85.
23. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007;9:209-17.
24. Peterson GE. Analog insulin detemir for patients with type 1 and type 2 diabetes: a review. Diabetes Metab Syndr Obes. 2009;2:31-6.
25. Wright A, Burden ACF, Paisey RB, Cill CA, Holman RR, and the UK Prospective Diabetes Study Group. Sulphonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-6.
26. Riedel AA, Heien H, Wogen J, Plauschinat CA. Secondary failure of glycemic control for patients adding thiazolidinedione or sulphonylurea therapy to metformin regimen. Am J Manag Care. 2007;13: 457-63.
27. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-74.
28. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ. 2006;174:645-6.